Thor Medical ASA - Share Option grant
Thor Medical ASA (TRMED) · publisert 2026-01-21 17:42 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Therese Kvehaugen | Person discharging managerial responsibilities EVP HR | other | 700 000 | 0 NOK | 2026-01-21 | NO0010597883 | Outside trading venue | rules · til gjennomgang |
| Mathias Reierth | Person discharging managerial responsibilities Head of Communications | other | 600 000 | 0 NOK | 2026-01-21 | NO0010597883 | Outside trading venue | rules · til gjennomgang |
Vedlegg
- Download announcement as PDF.pdf (tekst hentet ut)
- Thor Medical - primary insider notification MAR- EVP HR.pdf (tekst hentet ut)
- Thor Medical - primary insider notification MAR - Head of Communications.pdf (tekst hentet ut)
Meldingstekst
21.1.2026 18:42:45 CET | Thor Medical ASA | Mandatory notification of trade
primary insiders
Oslo, Norway, 21 January 2026 - Thor Medical ASA (the "Company") has granted
share options to employees and senior management.
In connection with the appointments of Therese Kvehaugen as Executive Vice
President Human Resources and Mathias Reierth as Head of Communications &
Corporate Affairs, the Company has today granted 700,000 and 600,000 share
options to them, respectively. The options are granted in accordance with the
Company's guidelines for remuneration of senior executives and board members, as
approved by Thor Medical's annual general meeting held 11 April 2024.
Each option provides a right to acquire one share at the exercise price, equal
to the volume-weighted share price over the last ten trading days prior to
grant. The options will vest over the period from 1 February 2026 to 1 August
2027, subject to continued employment with the Company, with a first tranche
corresponding to 2/3 of the granted options vesting 12 months after the grant.
The remaining options will vest monthly up until 1 August 2027.
Notifications of the transaction in accordance with the Market Abuse Regulation
Article 19 are attached to this announcement.
For further information please contact:
Brede Ellingsæter
Chief Financial Officer
Tel: +47 472 38 440,
Email: brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit https://www.thormedical.com.
This information is subject to the disclosure requirements pursuant to the
Market Abuse Regulation article 19 and section 5-12 of the Securities Trading
Act.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18780310/6730/Download%20announce
ment%20as%20PDF.pdf
Thor Medical - primary insider notification MAR- EVP HR.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18780310/6728/Thor%20Medical%20-%
20primary%20insider%20notification%20MAR-%20EVP%20HR.pdf
Thor Medical - primary insider notification MAR - Head of Communications.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18780310/6729/Thor%20Medical%20-%
20primary%20insider%20notification%20MAR%20-%20Head%20of%20Communications.pdf